Eosinophilic Esophagitis
Top in GI: Gallstone disease and pancreatic cancer; new eosinophilic esophagitis drug
A presenter at Digestive Disease Week reported that gallstone disease may be a predictor of pancreatic cancer.
FDA approves first treatment for eosinophilic esophagitis in the US
FDA accepts supplemental biologics license application for Dupixent for EoE
Regeneron Pharmaceuticals Inc. and Sanofi announced that the FDA accepted for priority review a supplemental biologics license application for Dupixent 300 mg for adults and children aged 12 years and older with eosinophilic esophagitis.
Top in GI: AI-assisted colonoscopy, FDA denial of budesonide for eosinophilic esophagitis
A new study showed that artificial intelligence-assisted colonoscopy increased the adenoma detection rate in patients at average risk for colorectal cancer. It was the top story in gastroenterology last week.
Dupilumab induces eosinophilic esophagitis remission among children with atopic conditions
Dupilumab effectively induced remission of esophageal disease among children with eosinophilic esophagitis treated with the agent for atopic conditions, according to a study published in Annals of Allergy, Asthma & Immunology.
Is FDA approval in sight for emerging EoE therapies?
Over the years, there have been many advances in the pathologic understanding of eosinophilic esophagitis, but FDA-approved treatment options have lagged.
Budesonide for EoE: Why the FDA denial is so hard to swallow
In December 2021, the FDA issued a complete response letter to Takeda Pharmaceutical Company for its new drug application for budesonide oral suspension for the treatment of eosinophilic esophagitis in adolescents and adults.
Weekly dupilumab may induce histologic remission of eosinophilic esophagitis
PHOENIX — Dupilumab significantly improved swallowing ability and reduced eosinophils in the esophagus, indicating histologic remission, compared with placebo, according to results from the phase 3 LIBERTY-EoE-TREET study.
FDA rejects new drug application from Takeda for budesonide for EoE
Takeda Pharmaceutical Company Limited announced it received an FDA complete response letter in response to its new drug application for TAK-721 for the treatment of eosinophilic esophagitis, according to a release.
Budesonide improves histologic, symptom response in pediatric EoE
Budesonide oral suspension improved histologic, endoscopic and symptom response compared with placebo among pediatric patients with eosinophilic esophagitis, according to a study.